European Penny Stocks To Watch In October 2026

As European markets navigate volatility driven by elevated oil prices and rising sovereign bond yields, investors are keeping a close eye on opportunities that may arise from smaller or newer companies. Penny stocks, though an outdated term, continue to represent a segment of the market where value and growth potential can coexist. By focusing on those with strong financials and growth prospects, investors might uncover promising candidates poised for long-term success.

Let's take a closer look at a couple of our picks from the screened companies.

Meta Estate Trust (BVB:NC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Meta Estate Trust S.A. is a company that invests in real estate in Romania with a market capitalization of RON73.14 million.

Operations: The company's revenue is entirely generated from its operations in Romania, amounting to RON14.76 million.

Market Cap: RON73.14M

Meta Estate Trust S.A., with a market cap of RON73.14 million, operates in Romania's real estate sector. Despite its low revenue of RON4.36 million for the recent half-year, the company maintains a satisfactory net debt to equity ratio of 5.5% and has short-term assets exceeding both short- and long-term liabilities. Its Price-To-Earnings ratio is favorable at 8.6x against the local market average, indicating potential value for investors focused on penny stocks. However, the company's earnings growth has been negative recently, and profit margins have declined from last year’s figures, suggesting some caution may be warranted.

• Get an in-depth perspective on Meta Estate Trust's performance by reading our balance sheet health report here.
• Assess Meta Estate Trust's previous results with our detailed historical performance reports.

BioPorto (CPSE:BIOPOR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: BioPorto A/S is an in-vitro diagnostics company that develops biomarker tests for early detection of kidney injury in critically ill patients across Denmark, Europe, North America, and Asia, with a market cap of DKK532.24 million.

Operations: BioPorto generates revenue from various segments, including Antibodies (DKK8.51 million), ELISA Kits (DKK1.26 million), and NGAL Tests (DKK28.48 million), along with a small contribution from Royalty and Other Revenue (DKK0.12 million).

Market Cap: DKK532.24M

BioPorto A/S, with a market cap of DKK532.24 million, is navigating the penny stock landscape with a focus on biomarker tests for kidney injury detection. Despite being unprofitable, it has reduced losses by 0.3% annually over five years and remains debt-free. Short-term assets of DKK99.4 million comfortably cover liabilities, supporting financial stability amid high share price volatility. Recent earnings showed improvement with net income rising to DKK35.93 million in Q2 2026 from a loss the previous year, though sales declined to DKK6.9 million from DKK10.59 million year-on-year, indicating mixed performance signals for investors.

• Unlock comprehensive insights into our analysis of BioPorto stock in this financial health report.
• Examine BioPorto's earnings growth report to understand how analysts expect it to perform.

Herkules (WSE:HRS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Herkules S.A. operates in Poland, focusing on hoisting equipment rental and oversize load shipping, with a market cap of PLN50.84 million.

Operations: Herkules S.A. has not reported any specific revenue segments.

Market Cap: PLN50.84M

Herkules S.A., with a market cap of PLN50.84 million, has shown resilience in the penny stock sector by becoming profitable over the past year. Despite a net loss of PLN2.45 million for the half-year ending June 2026, this marks an improvement from a larger loss previously. The company's revenue increased to PLN49.23 million from PLN44.05 million year-on-year, reflecting growth potential. Herkules's debt is well-managed and covered by operating cash flow at 205%, and its return on equity stands high at 29.4%. However, short-term liabilities exceed short-term assets, which may warrant caution for investors.

• Take a closer look at Herkules' potential here in our financial health report.
• Learn about Herkules' historical performance here.

Make It Happen

• Gain an insight into the universe of 264 European Penny Stocks by clicking here.
• Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com